drugset / Trial / NCT06218199

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

NCT06218199

RandomizedParallel-groupOpen-labelTreatment

Summary

The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.

Timeline

Start
2021-07-08
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bumetanide Small molecule 1 mg Oral
Comparator Furosemide Other / unclassified 40 mg Oral
Comparator Furosemide Other / unclassified 480 mg Oral
Comparator Hydralazine Small molecule 10 mg Oral
Comparator Isosorbide Dinitrate Other / unclassified 10 mg Oral
Comparator Torsemide Other / unclassified 20 mg Oral
Comparator sacubitril/valsartan Unknown 24 mg Oral
Comparator sacubitril/valsartan Unknown 49 mg Oral